Psilocybin + PIMAVANSERIN for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Jun 2024: Trial registered, NCT06455293
  2. 19 Aug 2024: Trial started, NCT06455293

The trials

NCT06455293: Psilocybin Therapy for Depression in Parkinson's Disease

State
Under way
Phase
Phase 2
People
60 planned
Started
19 Aug 2024
Primary completion
Jun 2027
Arms
Psilocybin Administration Session 1, Psilocybin Administration Session 2
Results
None posted
  1. 12 Jun 2024: Trial registered
  2. 19 Aug 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.